RxDoctor Payments Data

Joseph Cherian, MD

Cardiovascular Disease · Coon Rapids, MNNPI 1629246707

Payments from drug & device makers

$16,849in general payments, 2019–2025

Across 48 payments — averaging $351.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$14K
  • Heartflow, Inc.$1K
  • Cvrx, Inc.$396
  • Abbott$206
  • Medtronic$170
  • Boston Scientific$109
  • plus $176 from 6 others

What the payments were for

  • Food & beverage$2,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,849 in reported general payments places this provider in the 65th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$57,614
Medicare patients
608
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$146,549
JardianceEmpagliflozin44$61,304
XareltoRivaroxaban41$44,862
EntrestoSacubitril/Valsartan14$22,768
Metoprolol Succinate239$3,909
Bumetanide27$2,638
Rosuvastatin Calcium203$2,546
Atorvastatin Calcium140$2,018
Losartan Potassium146$1,630
Potassium Chloride43$1,457
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,325
Carvedilol84$1,093
Lisinopril100$1,052
Metoprolol Tartrate85$979
Spironolactone85$821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$146,549133 claims
NovartisEntresto$16$22,76814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Coon Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →